摘要
目的观察匹多莫德对支原体肺炎患儿免疫功能及炎性因子的影响。方法研究对象为2013年5月~2015年5月在我院就诊的支原体肺炎患儿共100例,所有患儿根据治疗方法不同分为观察组和对照组,每组各50例,两组均予退热、止咳、解痉等治疗,对照组予阿奇霉素,观察组加用匹多莫德口服液。比较两组治疗后的临床疗效及两组治疗前后临床症状积分的变化情况,并检测两组患者治疗前后免疫功能及炎症因子的变化情况。结果观察组总有效率为96.00%,明显高于对照组的78.00%,两组总有效率组间比较,差异有统计学意义(P<0.05)。观察组的临床症状积分显著低于对照组,差异有统计学意义(P<0.05)。观察组和对照组治疗后CD4^+、CD4^+/CD8^+分别较治疗前显著升高,且观察组治疗后CD4^+、CD4^+/CD8^+的水平显著高于对照组。观察组和对照组治疗后IL-4、IL-6、IL-10分别较治疗前显著降低,且观察组治疗后IL-4、IL-6、IL-10水平显著低于对照组(P<0.05)。结论匹多莫德可以提高支原体肺炎的疗效,提高免疫功能,抑制炎症反应,值得推广和应用。
Objective To observe the influence of pidotimod on immunity and inflammatory factors in children with mycoplasma pneumonia. Methods A total of 100 children with mycoplasma pneumonia treated in our hospital from May 2013 to May 2015 were selected and divided into observation group （n=50） and control group （n=50） according to therapeutic methods. Patients in both groups were given treatment to bring down fever and relieve cough and spasm. Patients in the control group were given＇ azithromycin, and patients in the observation group were additionally given pidotimod oral liquid for 4 weeks as a course of treatment. The clinical efficacy after treatment and the changes of clinical symptom scores before and after treatment were compared between two groups. The changes of immunity and inflammatory factors before and after treatment were detected in both groups. Results The overall response rate in the observation group was 96.00%, which was significantly higher than the 78.00% in the control group （P〈0.05）. The clinical symptom scores in the observation group were significantly lower than those in the control group （P〈0.05）. The levels of CD4^＋ and CD4^＋/CD8^＋ after treatment were significantly higher than those before treatment in both groups, and the levels of CD4^＋ and CD4^＋/CD8^＋ after treatment were significantly higher in the observation group than in the control group. The levels of IL-4, IL-6, and IL-10 after treatment were significantly lower than those before treatment in both groups, and the levels of IL-4, IL-6, and IL-10 after treatment were significantly lower in the observation group than in the control group （P〈0.05）. Conclusion Pidotimod can improve the efficacy on mycoplasma pneumonia, strengthen immunity, and inhibit inflammatory response, thus is worthy to be promoted.
出处
《中国现代医生》
2016年第17期48-50,53,共4页
China Modern Doctor
基金
浙江省医药卫生科技计划项目(2014KYB212)
